Literature DB >> 26828565

Optimized Cryopreservation and Banking of Human Bone-Marrow Fragments and Stem Cells.

Gianluca Carnevale1,2, Alessandra Pisciotta1, Massimo Riccio1, Sara De Biasi1, Lara Gibellini1, Adriano Ferrari2,3, Giovanni B La Sala2,4, Giacomo Bruzzesi5, Andrea Cossarizza1,2, Anto de Pol1,2.   

Abstract

Adult mesenchymal stem cells are a promising source for cell therapies and tissue engineering applications. Current procedures for banking of human bone-marrow mesenchymal stem cells (hBM-MSCs) require cell isolation and expansion, and thus the use of large amounts of animal sera. However, animal-derived culture supplements have the potential to trigger infections and severe immune reactions. The aim of this study was to investigate an optimized method for cryopreservation of human bone-marrow fragments for application in cell banking procedures where stem-cell expansion and use are not immediately needed. Whole trabecular fragments enclosing the bone marrow were stored in liquid nitrogen for 1 year in a cryoprotective solution containing a low concentration of dimethyl sulfoxide and a high concentration of human serum (HuS). After thawing, the isolation, colony-forming-unit ability, proliferation, morphology, stemness-related marker expression, cell senescence, apoptosis, and multi-lineage differentiation potential of hBM-MSCs were tested in media containing HuS compared with hBM-MSCs isolated from fresh fragments. Human BM-MSCs isolated from cryopreserved fragments expressed MSC markers until later passages, had a good proliferation rate, and exhibited the capacity to differentiate toward osteogenic, adipogenic, and myogenic lineages similar to hBM-MSCs isolated from fresh fragments. Moreover, the cryopreservation method did not induce cell senescence or cell death. These results imply that minimal processing may be adequate for the banking of tissue samples with no requirement for the immediate isolation and use of hBM-MSCs, thus limiting cost and the risk of contamination, and facilitating banking for clinical use. Furthermore, the use of HuS for cryopreservation and expansion/differentiation has the potential for clinical application in compliance with good manufacturing practice standards.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26828565     DOI: 10.1089/bio.2015.0001

Source DB:  PubMed          Journal:  Biopreserv Biobank        ISSN: 1947-5543            Impact factor:   2.300


  5 in total

1.  Activation of Fas/FasL pathway and the role of c-FLIP in primary culture of human cholangiocarcinoma cells.

Authors:  Gianluca Carnevale; Guido Carpino; Vincenzo Cardinale; Alessandra Pisciotta; Massimo Riccio; Laura Bertoni; Lara Gibellini; Sara De Biasi; Lorenzo Nevi; Daniele Costantini; Diletta Overi; Andrea Cossarizza; Anto de Pol; Eugenio Gaudio; Domenico Alvaro
Journal:  Sci Rep       Date:  2017-10-31       Impact factor: 4.379

Review 2.  Umbilical cord tissue cryopreservation: a short review.

Authors:  Irina Arutyunyan; Timur Fatkhudinov; Gennady Sukhikh
Journal:  Stem Cell Res Ther       Date:  2018-09-15       Impact factor: 6.832

3.  Titanium Surface Properties Influence the Biological Activity and FasL Expression of Craniofacial Stromal Cells.

Authors:  Enrico Conserva; Alessandra Pisciotta; Francesco Borghi; Milena Nasi; Simone Pecorini; Laura Bertoni; Anto de Pol; Ugo Consolo; Gianluca Carnevale
Journal:  Stem Cells Int       Date:  2019-01-13       Impact factor: 5.443

4.  Role of PD-L1 in licensing immunoregulatory function of dental pulp mesenchymal stem cells.

Authors:  Rosanna Di Tinco; Giulia Bertani; Alessandra Pisciotta; Laura Bertoni; Elisa Pignatti; Monia Maccaferri; Jessika Bertacchini; Paola Sena; Antonio Vallarola; Rossella Tupler; Stefania Croci; Martina Bonacini; Carlo Salvarani; Gianluca Carnevale
Journal:  Stem Cell Res Ther       Date:  2021-12-04       Impact factor: 6.832

Review 5.  Cryostorage of Mesenchymal Stem Cells and Biomedical Cell-Based Products.

Authors:  Daria D Linkova; Yulia P Rubtsova; Marfa N Egorikhina
Journal:  Cells       Date:  2022-08-29       Impact factor: 7.666

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.